Mavacoxib is primarily used in veterinary medicine as a long-acting, non-steroidal anti-inflammatory drug (NSAID) specifically designed for dogs. It is commonly prescribed to manage pain and inflammation associated with osteoarthritis, a degenerative joint disease that affects mobility and quality of life in dogs. Due to its extended duration of action, Mavacoxib requires less frequent dosing compared to other NSAIDs, making it convenient for pet owners and reducing stress for the animals. It works by selectively inhibiting the COX-2 enzyme, which is involved in the inflammatory process, while minimizing effects on the COX-1 enzyme, thereby reducing the risk of gastrointestinal side effects. Veterinarians often recommend it as part of a comprehensive treatment plan that may include weight management, physical therapy, and other supportive care measures to improve joint health and overall well-being in affected dogs.